Drugs / REN-1654
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00107055 | Dec 2003 → Apr 2005 | lumbar disk disease, radiculopathy, sciatica | Renovis | Unknown | No outcome recorded |
| Phase 2 | NCT00099528 | Aug 2003 → Dec 2004 | herpes zoster, neuralgia | Renovis | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | REN 1654 | “This is a multi-center, randomized, double-blind, placebo-controlled study to determine the efficacy and tolerability of REN-1654 in subjects with sciatica. After screening and...” NCT00107055 ↗ |
| Route | Oral | “receive 30 or 100 mg REN-1654 by mouth (p.o.)” NCT00099528 ↗ |